2/10/69
Dear Dr O'Brien --
Thank you for your painstaking and thoughtful reply to my questions.
I will of course honor your confidences. However, I would encourage you to bring any abuses of trust in grant selection to the attention of Dr. Maiston [sic] as Director of the NIH
Your critical survey of clinical test methodology in the evaluation of indomethacin was most illuminating. Quite apart from basis of financial interest, I suspect that misguided optimism may be the worst culprit!
I will plan to write something further about tighter controls on licenses to prescribe new drugs. Thank you for your suggestions.
Sincerely,
Joshua Lederberg